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Plasma level of lipoprotein Lp(a) is high in predialysis or
hemodialysis, but not in CAPD
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Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis,
but not in CAPD. Plasma Lp(a) lipoprotein level was determined in
chronic renal failure (CRF) patients, 24 before initiation of dialysis, 18
undergoing hemodialysis, and 24 on continuous ambulatory peritoneal
dialysis (CAPD). Eighteen healthy subjects were studied as controls.
Median of Lp(a) level in both predialysis and dialysis patients was
significantly increased: 23.5 mgldl (range: 0 to 109) and 24.0 mg/dl
(range: 1.4 to 90), respectively, as compared to healthy controls: 4.7
mg/dl (range: 1.8 to 27; P <0.001). By contrast, the median Lp(a) level
in CAPD patients, 2.4 mgldl (range: 0 to 39.5), was similar to the control
group. Whether the CAPD procedure reduces the Lp(a) level in CRF
patients has to be established in a prospective study.
Lipoprotein (a) [Lp(a)] is an LDL particle which has an
additional protein apo (a). The (a) antigen [1] is cross linked by
disulfide bonds to apolipoprotein B [21. Metabolic studies have
shown that Lp(a) is not a product derived from other apolipo-
protein B containing particles, but probably is secreted by the
liver as a distinct mature lipoprotein. Clinical interest in this
lipoprotein has been aroused in that it may be an independent
risk factor for atherosclerosis. Genetically determined high
concentrations of Lp(a) have been strongly associated with
premature cardiovascular disease [3], myocardial infarction [4],
and cerebrovascular disease [5]. As elevated Lp(a) levels have
been found recently in CRF patients undergoing hemodialysis
[6], we studied this lipoprotein in predialysis CRF patients, and
in CRF patients who are on chronic ambulatory peritoneal
dialysis (CAPD).
Methods
Blood samples were drawn after an overnight fast. For
hemodialysis patients the blood was sampled before an hemo-
dialysis session, prior to heparin administration.
Eighteen patients with chronic renal failure and receiving
hemodialysis were investigated. Hemodialysis was performed
for approximately five hours, three times a week. The patients
had been on hemodialysis for 89 22 months, and dialyzed
with an acetate buffered dialysate. Twenty-four patients on
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CAPD for 19 14 months were investigated. CAPD was
performed with four, two-liter bags with 1.5% glucose daily. A
group of 24 predialyzed CRF patients was also investigated; all
patients had advanced renal failure with mild or moderate
uremic symptoms. A group of 18 healthy volunteers selected in
a center for preventive medicine (Institut Pasteur, Lille) was
used as a control. Clinical and biochemical data appear in Table
Lp(a) concentrations were measured using a selective two-
site ELISA procedure with monoclonal antibodies against
apo(a) and apo B, as previously described [7], and are shown in
Table 2. Cholesterol and triglycerides were measured enzymat-
ically (Boehringer, Mannheim, Germany).
Statistical analysis was performed by one-way ANOVA,
multiple comparison (Scheffe type). Since the Lp(a) distribution
was skewed, statistical comparisons were done after logarith-
mic transformation of Lp(a) values.
Results
The lipid profile of CRF patients receiving hemodialysis was
characterized by increased triglycerides as compared to con-
trols. The Lp(a) level in hemodialysis patients averaged three
times the control level (26.3 20.9 and 6.7 6.0 mgldl,
respectively, P C 0.001). CAPD patients had elevated levels of
cholesterol and triglycerides; their Lp (a) levels were similar to
that of controls (5.8 9.0 mg/dl; Fig. 1). Significant differences
were also observed between the two dialysis procedures;
CAPD patients showed elevated plasma cholesterol level and
reduced Lp(a) level when compared to hemodialysis patients.
The lipids and Lp(a) of predialysis patients were similar to those
of hemodialysis patients.
The prevalence of high level Lp(a) (>30 mgldl) in CRF
patients was 4% in CAPD, 44% in predialyzed patients and 28%
in hemodialyzed patients, which was in agreement with previ-
ously reported data [8].
Discussion
High Lp(a) levels were found in predialysis and hemodialysis
CRF patients as compared to controls. By contrast, Lp(a) level
in CAPD patients was in the normal range. The high Lp(a) level
could not be related to proteinuria [91, at least in hemodialysis
patients who generally had no residual diuresis. Recently,
Takegoshi et al [9] have found elevated Lp(a) concentration in
diabetic nephropathy patients; however, the difference in Lp(a)
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Table 1. Clinical and biochemical data on the subjects
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Control CAPD Hemodialysis Predialysis
Sex(M/F) 18(10/8) 24(13/11) 18(11/7) 24(14/10)
Age years
BMI kg/rn2
52.2 (3.2)
23.5 (1.0)
58.5 (4.1)
24.2 (0.8)
53.8 (3.6)
21.9 (0.7)
50.7 (3.8)
22.8 (1.3)
Plasma urea rng/dl 33 (2) 136 (12) 91(11) 109 (9)
Plasma creatinine 1.03 (0.03) 8.8 (0.7) 13.5 (0.7) 4.02 (0.38)
mg/dl
Etiology
CGN 5 6 4
PD 2 2 6
VC 6 2 4
CIN 4 4 7
DN 3 — —
Others 3 4 2
Unknown 1 — 1
Values are mean (sEM), except number of subjects. Abbreviations
are: BML, body mass index; CGN, chronic glomerulonephntis; PD,
polycystic disease; VC, vascular causes; CIN, chronic interstitial
nephritis; DN, diabetic nephropathy.
Table 2. Lipids and Lp(a) concentrations in plasma of controls and
patients with chronic renal failure
Chol TG
Lp(a) mg/dl
Mean SD Median Range
Controls (A) 212.8 85.9 6.7 6.0 4.7 1.8—27.0(N = 18) 27.0 24.7
Hemodialysjs (B) 199.9 187.3 26.3 20.9 24.0 1.4—90.0
(N= 18) 76.7 120.1
CAPD (C) 284.2 190.3 5.8 9.0 2.4 0—39.5(N = 24) 74.0 98.1
Predialysis (D) 227.9 177.7 30.8 27.4 23.5 0—109(N = 24) 41.8 109.1
P values
A vs. B <0.05 <0.01
A vs. C <0.01 <0.05
A vs. D <0.05 <0.001
B vs. C <0.001 <0.01
B vs. D
C vs. D <0.05 <0.001
level between predialysis and CAPD patients could not be
ascribed to a different proportion in the number of diabetic
patients in these two groups (0/24 and 3/24, respectively).
Since, in this study, Lp(a) level was determined by the
Lp(a):B method, we can also raise the hypothesis that Lp(a)
particles could circulate as Lp(a) free of apoB, leading us to
underestimate Lp(a) level. In this issue, we have assessed Lp(a)
with a previously described method [7] using two anti-apo(a)
monoclonal antibodies on 10 CAPD, and 10 hemodialysis
patients. The achieved results (5.6 5.9 and 44.0 27.0 mg/dl,
respectively) confirm those obtained by the Lp(a):B method.
Though preliminary, our results suggest that the Lp(a) level is
increased in uremia, and that CAPD, but not hemodialysis,
corrects this. However, we cannot confirm in this study that the
Lp(a) level in uremic patients was lowered by CAPD, since the
Lp(a) level was not measured prior to initiation of dialysis.
Moreover, since the number of patients was small (N = 24), it
is possible that the patients on CAPD all had a normal level of
Lp(a) before they went on dialysis.
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Fig. 1. Plasma Lp (a) concentrations in control and uremic patients.
Factors regulating synthesis, secretion and metabolism of
Lp(a) are as yet unknown. It is possible that continual glucose
absorption from the peritoneum modulates the synthesis rate of
Lp(a) in CAPD patients. The exact mechanism remains to be
further clarified.
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Abbreviations are: Chol, cholesterol; TG, triglycerides; results are
mean SD.
